E24.2 Drug-induced Cushing's syndrome

Name of the Condition

• Drug-induced Cushing's syndrome (ICD-10 Code: E24.2)

Summary

Drug-induced Cushing's syndrome is a form of hypercortisolism resulting from prolonged exposure to exogenous corticosteroid medications. Unlike endogenous causes, this condition arises from external sources of cortisol or synthetic glucocorticoids, leading to the characteristic signs and symptoms of Cushing's syndrome. The excess hormone disrupts normal metabolic and physiological processes, requiring careful management to mitigate complications.

Causes

The primary cause is the long-term use of corticosteroid medications, such as prednisone, dexamethasone, or hydrocortisone, prescribed for inflammatory, autoimmune, or immunosuppressive conditions. These drugs mimic cortisol's effects, leading to iatrogenic hypercortisolism. The condition may also occur with inhaled or topical corticosteroids in rare cases, particularly with high doses or prolonged use.

Risk Factors

• Prolonged use of systemic corticosteroids (e.g., for asthma, rheumatoid arthritis, or organ transplantation)
• High-dose or long-term topical/inhaled corticosteroid therapy
• Use of corticosteroids in pediatric or elderly populations
• Concurrent use of medications that enhance corticosteroid effects (e.g., certain antifungals)

Symptoms

• Weight gain, especially in the face, neck, and abdomen
• Rounded, moon-shaped face (moon facies)
• High blood pressure (hypertension)
• Thin skin with easy bruising and purple stretch marks (striae)
• Muscle weakness and fatigue
• Mood changes, including irritability or depression
• Irregular menstrual cycles in women
• Increased thirst and urination

Diagnosis

Diagnosis involves a thorough medication history to identify corticosteroid use, followed by clinical evaluation of symptoms. Laboratory tests may include cortisol levels, though results can be confounded by exogenous steroids. Imaging is typically unnecessary unless other causes of Cushing's syndrome are suspected. Discontinuation or dose reduction of the offending drug, when feasible, often confirms the diagnosis.

Treatment Options

Treatment focuses on reducing or discontinuing the causative corticosteroid, under medical supervision to avoid adrenal insufficiency. Gradual tapering is recommended for long-term users. Symptomatic management may include antihypertensives, glucose control, or bone protection. In cases where corticosteroids cannot be stopped, alternative therapies for the underlying condition may be explored.

Prognosis and Follow-Up

Prognosis is generally good with timely intervention, as symptoms often resolve after discontinuing the drug. However, recovery may take months, and some effects (e.g., skin changes) may persist. Regular follow-up is essential to monitor for adrenal insufficiency, metabolic changes, or recurrence of the underlying condition requiring corticosteroids.

Complications

• Adrenal insufficiency (if corticosteroids are abruptly stopped)
• Osteoporosis and fractures
• Type 2 diabetes or worsening glycemic control
• Increased infection risk
• Cardiovascular disease (e.g., hypertension, atherosclerosis)

Lifestyle & Prevention

• Use the lowest effective corticosteroid dose for the shortest duration.
• Explore non-steroidal alternatives for chronic conditions when possible.
• Maintain a balanced diet and regular exercise to support metabolic health.
• Monitor for symptoms and report changes to healthcare providers promptly.

When to Seek Professional Help

Seek medical attention if experiencing new or worsening symptoms of Cushing's syndrome, especially if taking corticosteroids. Immediate care is needed for signs of adrenal crisis (e.g., severe fatigue, low blood pressure, or confusion) after stopping corticosteroids.

Tips for Medical Coders

Document the specific corticosteroid agent, duration of use, and underlying condition being treated, as these details support the diagnosis. Ensure the code E24.2 is used only when drug-induced Cushing's syndrome is confirmed, distinguishing it from endogenous causes. Include any relevant clinical notes about tapering or discontinuation plans, as these may impact coding accuracy and reimbursement.